Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma

Chest

Volumn 121, Issue 4, 2002, Pages 1028-1035

  O’connor, Richard D ^a   O’donnell, John C ^b   Pinto, Lionel A ^c   Wiener, Douglas J ^c   Legorreta, Antonio P ^d  

^a Sharp Rees Stealy Medical Group   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Health Benchmarks   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Asthma; Dual controller therapy; Fluticasone; Inhaled corticosteroids; Leukotriene modifiers; Pharmacoeconomic evaluation; Salmeterol

Indexed keywords

CORTICOSTEROID DERIVATIVE; FLUTICASONE; SALMETEROL;

ADULT; ARTICLE; ASTHMA; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EMERGENCY WARD; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; OUTPATIENT; PATIENT; PRESCRIPTION; PRIORITY JOURNAL; REDUCTION; REGRESSION ANALYSIS; RESPIRATORY TRACT CANCER; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

EID: 0036203840     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.4.1028     Document Type: Article

References (20)

1. Forecasted state-specific estimates of self-reported asthma prevalence-United States, 1998
2. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma
3. Inhaled salme-terol and fluticasone: A study comparing monotherapy and combination therapy in asthma
4. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice daily and budesonide 800 μg twice daily in the treatment of adults and adolescents with asthma
5. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
6. Salmeterol powder provides significantly better benefit than the addition montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy
7. Using claims data to measure and improve the MMR immunization rate in an HMO
8. Geographic variations in the use of service: Do they have any clinical significance?
9. The cost of asthma in the emergency department and hospital
10. Developing a tool for analyzing medical care utilization of adult asthma patients in indemnity and managed care plans: Can an episodes of care framework be used?
11. Alternative statistical techniques to evaluate linearity
12. Heterogeneity of variance in clinical data
13. Economic impact of salmeterol versus leukotriene modifiers in patients with chronic asthma
14. The combination of salmeterol and fluticasone improves asthma-related health outcomes at lower cost compared to the combination of inhaled corticosteroids and montelukast